Share chart Geron Corporation
About
Корпорация "Герон", клиническая биофармацевтическая компания на поздней стадии, специализируется на разработке и коммерциализации методов лечения гематологических миелоидных злокачественных новообразований. Он обладает правами на иметелстат, ингибитор теломеразы в клинических испытаниях фазы 2F3, который ингибирует неконтролируемую пролиферацию злокачественных клеток-предшественников при гематологических миелоидных злокачественных опухолях, чтобы уменьшить дисфункциональную продукцию клеток крови и обеспечить восстановление нормальной продукции клеток крови.
More detailsP/S | 537.41 |
---|---|
P/BV | 1.83 |
EV/EBITDA | -3.29 |
EBITDA | -0.0717 |
Цена ао | 4.06 |
Сайт | http://www.geron.com |
Число акций ао | 0.57065 млрд |
Выручка | 0.00046 |
Див.доход ао | 0 |
ISIN | US3741631036 |
Валюта | usd |
IPO date | 1996-06-30 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Change price per day: | +0.7444% (4.03) |
---|---|
Change price per week: | -4.92% (4.27) |
Change price per month: | -9.98% (4.51) |
Change price per 3 month: | -14.71% (4.76) |
Change price per half year: | +8.85% (3.73) |
Change price per year: | +128.09% (1.78) |
Change price per 3 year: | +144.58% (1.66) |
Change price per 5 year: | +170.67% (1.5) |
Change price per year to date: | +106.09% (1.97) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Dividend, % | Dividend | Result of period | Buy before | Register closing date | Payment before |
---|---|---|---|---|---|
9.46% | 0.14 | II кв. 2014 | 18.07.2014 | 22.07.2014 | 06.08.2014 |
Institutions | Volume | Share, % |
---|---|---|
RA Capital Management, L.P. | 46202425 | 8.45 |
Blackrock Inc. | 42172679 | 7.71 |
Deep Track Capital, LP | 29583449 | 5.41 |
Vanguard Group Inc | 28564574 | 5.22 |
State Street Corporation | 25625606 | 4.69 |
Vivo Capital, LLC | 24143681 | 4.41 |
Tcg Crossover Management, Llc | 23375839 | 4.27 |
NEA Management Company, LLC | 22776409 | 4.16 |
Millennium Management LLC | 14730986 | 2.69 |
Geode Capital Management, LLC | 10943649 | 2 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 753.22k | 1964 (60 years) |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | 1975 (49 years) |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | 1962 (62 years) |
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1.53M | 1951 (73 years) |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | 1983 (41 year) |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | N/A | 1967 (57 years) |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 847.2k | 1964 (60 years) |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Secretary | ||
Mr. James Ziegler M.B.A. | Executive VP & Chief Commercial Officer |
Website: http://www.geron.com